Laguna Tech


Privately held medical technology company based in Irvine, California, developing investigational transcatheter aortic valve systems for treatment of aortic regurgitation and aortic stenosis. The company designs valve frames, valve tissue processing, and delivery systems; manufactures devices in certified cleanrooms; and has conducted first-in-human feasibility studies and early clinical case series. The organization holds granted patents and reports early clinical outcomes from investigational use.

Industries

Manufacturing
Medical Equipment Manufacturing

Nr. of Employees

small (1-50)

Laguna Tech


Patents

Prosthetic heart valve device, delivery system, interventional system and related method

US-12226313-B2

View Details

Prosthetic heart valve device

US-11806233-B2

View Details

Products

Balloon-expandable transcatheter aortic valve system (investigational)

Investigational balloon-expandable transcatheter aortic valve system engineered to address aortic regurgitation and aortic stenosis, featuring multiple support arms for anchoring, low valve height, and a low-profile covered delivery system.

Self-expanding transcatheter aortic valve system (investigational)

Investigational single-piece self-expanding transcatheter valve engineered with a low profile and support arms to facilitate positioning and treatment of aortic regurgitation.

Expertise Areas

  • Transcatheter heart valve design
  • Delivery system engineering
  • Feasibility and first-in-human clinical trials
  • Cleanroom medical device manufacturing
  • Show More (3)

Key Technologies

  • Transcatheter aortic valve replacement (TAVR) systems
  • Balloon-expandable valve mechanisms
  • Self-expanding valve mechanisms
  • Low-profile deflectable delivery catheters (16F)
  • Show More (3)

News & Updates

Press release reporting that five patients were implanted with the investigational balloon-expandable valve system at a single center in one day as part of an ongoing feasibility trial; all patients had complete resolution of disease immediately post-procedure and were discharged within 24–48 hours.

Press release reporting completion of initial first-in-human clinical cases with investigational balloon-expandable and self-expanding valve systems, with early cases reporting resolution of aortic regurgitation at 30-day follow-up.

Announcement that the first patient was treated in a first-in-human clinical trial of an investigational self-expanding transcatheter valve system, with reported immediate and 30-day resolution of aortic regurgitation in the initial case.

Company-reported completion of six clinical cases for the investigational valve with reported complete resolution in early follow-ups.

Announcement of a granted US patent strengthening the company's intellectual property position.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.